1. A perspective on molecular signalling dysfunction, its clinical relevance and therapeutics in autism spectrum disorder.
- Author
-
Purushotham, Sushmitha S., Reddy, Neeharika M. N., D'Souza, Michelle Ninochka, Choudhury, Nilpawan Roy, Ganguly, Anusa, Gopalakrishna, Niharika, Muddashetty, Ravi, and Clement, James P.
- Subjects
- *
AUTISM spectrum disorders , *THERAPEUTICS , *GENETIC variation , *INTELLECTUAL disabilities , *HUMAN genome - Abstract
Intellectual disability (ID) and autism spectrum disorder (ASD) are neurodevelopmental disorders that have become a primary clinical and social concern, with a prevalence of 2–3% in the population. Neuronal function and behaviour undergo significant malleability during the critical period of development that is found to be impaired in ID/ASD. Human genome sequencing studies have revealed many genetic variations associated with ASD/ID that are further verified by many approaches, including many mouse and other models. These models have facilitated the identification of fundamental mechanisms underlying the pathogenesis of ASD/ID, and several studies have proposed converging molecular pathways in ASD/ID. However, linking the mechanisms of the pathogenic genes and their molecular characteristics that lead to ID/ASD has progressed slowly, hampering the development of potential therapeutic strategies. This review discusses the possibility of recognising the common molecular causes for most ASD/ID based on studies from the available models that may enable a better therapeutic strategy to treat ID/ASD. We also reviewed the potential biomarkers to detect ASD/ID at early stages that may aid in diagnosis and initiating medical treatment, the concerns with drug failure in clinical trials, and developing therapeutic strategies that can be applied beyond a particular mutation associated with ASD/ID. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF